143 results about "Mycophenolic acid" patented technology

Drug eluting coating compositions are composed of at least one therapeutic agent dispersed in modified, biologically active binders. The therapeutic agents included in the coating composition are paclitaxel, sirolimus, tacrolimus, everolimus, actinomycin-D, dexamethasone, mycophenolic acid, cyclosporins, estradiol, and derivatives and analogs thereof. These therapeutic agents are applied to the surface of the medical device by a modified, biologically active binders. By using these biologically active binders, the therapeutic agents can be applied to at least one surface of a medical implant without using inert polymer carriers.

Ocular solutions containing at least one macrolide antibiotic and/or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial, and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surgery before insertion of a replacement intraocular lens, resulting in reduced posterior capsular opacification which may eliminate the need for a subsequent surgery. The solution may be one that is invasively administered, for example, an irrigation or volume replacement solution containing at least one macrolide antibiotic such as tacrolimus, sirolimus, everolimus, cyclosporine, and ascomycin, or mycophenolic acid. The solution may be one that is non-invasively or topically administered in the form of drops, ointments, gels, creams, etc. and may include eye lubricants and contact lens solutions.

The present invention provides improved devices and methods for minimizing and/or inhibiting restenosis and hyperplasia after intravascular intervention. In particular, the present invention provides luminal prostheses which allow for programmed and controlled mycophenolic acid delivery with increased efficacy to selected locations within a patient's vasculature to inhibit restenosis. An intraluminal delivery prosthesis may comprise an expansible structure and means on or within the structure for releasing mycophenolic acid at a rate selected to inhibit smooth muscle cell proliferation.

Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

Ocular solutions containing at least one macrolide antibiotic and/or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial, and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surgery before insertion of a replacement intraocular lens, resulting in reduced posterior capsular opacification which may eliminate the need for a subsequent surgery. The solution may be one that is invasively administered, for example, an irrigation or volume replacement solution containing at least one macrolide antibiotic such as tacrolimus, sirolimus, everolimus, cyclosporine, and ascomycin, or mycophenolic acid. The solution may be one that is non-invasively or topically administered in the form of drops, ointments, gels, creams, etc. and may include eye lubricants and contact lens solutions. The solution may contain a supratherapeutic concentration of agent(s) so that a therapeutic concentration of a topically administered solution accumulates in a diseased ocular structure sufficient to treat the disease. The agent(s) may be formulated with polymers or other components for extended or slow release to provide a substantially constant concentration over the course of treatment.

A method of treating a patient infected with a hepatitis C virus to decrease the severity of the viral infection. The method comprises concomitantly administering over a given period of time to the patient a first component and a second component. The first component consists of a pharmaceutical composition containing as an active ingredient a pharmaceutically acceptable salt or prodrug of mycophenolic acid in a therapeutically effective amount to decrease the severity of the viral infection. The second component consists of an injection solution containing as an active ingredient interferon-alpha or pegylated interferon-alpha in a therapeutically effective amount to decrease the severity of the viral infection. The components are concomitantly administered over a period of time at least sufficient to reduce the amount of HCV-RNA present in the peripheral blood of said patient to less than 100 copies/ml at 24 weeks after the end of treatment.

A method for mass spectrometric analysis of a saliva sample possibly containing mycophenolic acid or its metabolites mycophenolic acid phenyl glucuronide (MPAG) or mycophenolic acid acyl-glucuronide (Acyl-MPAG), including the steps: (a) providing a saliva sample containing one or more drug or metabolites; (b) deproteinating the sample; (c) separating the one or more drug or metabolites from the saliva sample; and (d) analyzing the one or more drug or metabolites using a mass spectrometer. The sample containing one or more MPA or metabolites is obtained from in an oral fluid based biological samples i.e. whole saliva or saliva obtained by chemical or mechanical stimulation or from specific salivary glands. The size of the sample contains one or more MPA or metabolites is at least about 100 microL. A kit for use in mass spectrometric analysis of a sample may contain one or more MPA or metabolites from saliva samples, comprising: (a) reagents for deproteinating of the saliva sample, including internal standards; (b) reagents for separating the one or more MPA or metabolites from the saliva sample; (c) reagents for analyzing the one or MPA or metabolites using a mass spectrometer; (d) a solution of one or more MPA or metabolites in saliva samples; and (e) instructions for analyzing the one or more MPA or saliva using a mass spectrometer. The kit includes (a) mobile phase solutions; (b) a chromatography column; and (c) a quality control specimen.

A preparing method of an enteric-coated preparation containing mycophenolic acid and salts thereof is disclosed. The method is characterized in that: the method includes directly mixing an enteric coating material and active components, adding a wetting agent suitable for medicinal preparations, uniformly mixing and granulating; and the enteric coating material is acrylic resin II and/or acrylic resin III. The method simplifies processes for preparing the enteric-coated preparation, and an independent coating process is not needed. Experiments show that: the preparation has better enteric properties than enteric-coated preparations in the prior art, release of the active components is not influenced by gastric emptying and foods, and the preparation provided by the invention has faster releasing speed. The preparation is stable in medicine effect, is in a form of granules and is convenient to take.

Provided are processes for preparation of mycophenolic acid.

The invention relates to a mycophenolic acid detection reagent as well as preparation and detection methods thereof and particularly relates to a mycophenolic acid homogeneous phase enzyme immunological detection reagent as well as preparation and detection methods thereof. The mycophenolic acid homogeneous phase enzyme immunological detection reagent comprises an anti-mycophenolic acid specific antibody, and an indication reagent for detecting an anti-mycophenolic acid specific antibody-mycophenolic acid compound; and the anti-mycophenolic acid specific antibody is prepared from mycophenolic acid immunogen immunological animals. The mycophenolic acid detection reagent has the beneficial effects that mycophenolic acid immunogen has strong specificity and high immunogenicity; the prepared anti-mycophenolic acid specific antibody has strong specificity and high valence and has no crossed reaction with common 62 types of medicines; the homogeneous phase enzyme immunological detection reagent containing the anti-mycophenolic acid specific antibody can be used for conveniently, rapidly and accurately determining the content of mycophenolic acid in a sample, and determining a plurality of samples on a full-automatic biochemical analyzer at the same time, so that the high-flux rapid determination for the mycophenolic acid is realized; and the accuracy is high, the specificity is strong, and the accuracy and the detection efficiency can be relatively greatly improved.

The invention discloses a method for solid state fermentation of mycophenolic acid, comprising the following steps: firstly, subcultured penicillium is inoculated into a seed culture medium for culture and then inoculated into a secondary seed culture medium for culture, so as to obtain secondary seed solution; and secondly, 0 to 2 portions of non-inert vector and 0.2 to 3 portions of inert vector are added into a container in mass portion and uniformly mixed, and then added with distilled water so as to make the relative humidity in the container be between 65 and 95 percent; and the mixture is sterilized for 0.5 to 1.5 hours, cooled until the temperature is between 22 and 28 DEG C, inoculated with 0.2 to 2 mass portions of the secondary seed solution and cultured for 90 to 360 hours at a temperature of between 24 and 26 DEG C and with the relative humidity between 70 and 95 DEG C. The method has low energy consumption, low investment and low pollution. Moreover, the culture medium in the method can not be shrunk and hardened, thereby the method is favorable for mass transfer and heat transfer; and the inert vector can be reused, thereby reducing the discharge amount of solid waste residue and being favorable for environmental protection.

The invention discloses a matrix-type preparation containing mycophenolic acid or a mycophenolic acid salt and a coated tablet thereof, and belongs to the technical field of medicinal preparations. The matrix-type preparation and the coated tablet thereof contain mycophenolic acid or a mycophenolic acid salt, and one or more pharmaceutically acceptable enteric polymers, one or more filling agents, one or more disintegrating agents and one or more lubricants and/or one or more adhesives. The matrix-type preparation containing mycophenolic acid or a mycophenolic acid salt and the coated tablet thereof can convey a drug to an upper end of the intestinal tract and release the drug so that precipitation of the drug in the stomach is avoided and bioavailability is improved.

The invention teaches derivatives of mycophenolic alcohol and methods of preparing immunogens and other conjugates useful in immunoassays for quantitatively measuring concentrations of mycophenolic acid (MPA) and/or active metabolites of MPA in patient specimens. Antibodies produced from the disclosed immunogens capable of binding to MPA with cross-reactivity of no more than 5% with inactive metabolites and commonly co-prescribed drugs. Further, immunoassays for measuring the concentration of MPA using such antibodies are taught.

The preparation process of mofetil mycophenolate includes the following successive steps: 1. dissolving mycophenolic acid and 2-morpyolinyl ethanol in the mixed solvent of toluene and xylene via stirring; 2. throwing in catalyst C1-6 fatty acid; 3. heating, stirring and refluxing for direct estification; 4. throwing in decolorizing agent active carbon; 5. throwing in ethyl acetate and decolorizing agent vitamin C, and washing with 10 % concentration sodium carbonate solution and water successively; and 6. heating, cooling to separate solid, washing with ethyl acetate and final vacuum drying to obtain the product. The preparation process of the present invention has short reaction time, low preparation cost, complete product decolorizing, yield up to 83 % and product purity over 99.6 %.